SCHEMBL20140445

SCHEMBL20140445

Cc1ncc(Cn2nc(C#N)c3ccccc32)cn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 2/20 0.41
CNR1 P21554 2/20 0.41
CNR2 P34972 2/20 0.41
ACHE P22303 1/20 0.41
F2 P00734 1/20 0.41
PLAU P00749 1/20 0.41
CTRB1 P17538 1/20 0.41
PDE5A O76074 1/20 0.40
GABRA1 P14867 1/20 0.39
GABRA5 P31644 1/20 0.39
KDM4E B2RXH2 2/20 0.38
CYP1A2 P05177 2/20 0.38
CYP2D6 P10635 2/20 0.38
GUCY1B2 O75343 1/20 0.38
CHRM2 P08172 1/20 0.38
HTR1A P08908 1/20 0.38
ADRA2A P08913 1/20 0.38
CHRM1 P11229 1/20 0.38
DRD1 P21728 1/20 0.38
SLC6A2 P23975 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28253344 0.83 ELANE (0.43) ELANECNR1CNR2ACHEF2
SCHEMBL4435378 0.83 CNR1 (0.54) ELANECNR1CNR2ACHEPDE5A
SCHEMBL20140443 0.82 ENPP2 (0.38) POLBTSHR
SCHEMBL20139770 0.82 PDE5A (0.37) PDE5A
SCHEMBL20139756 0.82 L3MBTL1 (0.51) ELANEL3MBTL1
SCHEMBL20140478 0.82 ELANE (0.35) ELANEGABRA1GABRA5TSHRL3MBTL1
SCHEMBL20140201 0.80 ESR1 (0.42) ELANEKDM4EPOLBTSHRL3MBTL1
SCHEMBL20534349 0.79 CNR1 (0.43) ELANECNR1CNR2ACHEF2
SCHEMBL19328149 0.79 CNR1 (0.43) ELANECNR1CNR2ACHEF2
SCHEMBL14853618 0.78 BUB1 (0.42) ELANECNR1CNR2ACHEF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435080-B2 sGC stimulators TISENTO THERAPEUTICS INC. (US) 2025-10-07 US disclosed
US-20220017515-A1 sGC STIMULATORS TISENTO THERAPEUTICS INC. 2022-01-20 US disclosed
US-20220017515-A1 sGC STIMULATORS TISENTO THERAPEUTICS INC. 2022-01-20 US disclosed
US-11180493-B2 SGC stimulators CYCLERION THERAPEUTICS, INC. (US) 2021-11-23 US disclosed
US-11180493-B2 SGC stimulators CYCLERION THERAPEUTICS, INC. (US) 2021-11-23 US disclosed
US-20200071318-A1 SGC STIMULATORS TISENTO THERAPEUTICS INC. 2020-03-05 US disclosed
US-20200071318-A1 SGC STIMULATORS TISENTO THERAPEUTICS INC. 2020-03-05 US disclosed
EP-3538520-A2 SGC STIMULATORS Cyclerion Therapeutics, Inc. (US) 2019-09-18 EP disclosed
WO-2018089330-A2 SGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2018-05-17 WO disclosed
WO-2018089330-A2 SGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2018-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200071318-A1 SGC STIMULATORS GUCY1A2, GMPS, PDE2A ELANE 2411/4885CNR1 1432/4885CNR2 1255/4885
US-20220017515-A1 sGC STIMULATORS GUCY1A2, PRKG1, PDE2A ELANE 2419/4885CNR1 1421/4885CNR2 1268/4885
US-12435080-B2 sGC stimulators GUCY1A2, PRKG1, PDE2A ELANE 2419/4885CNR1 1421/4885CNR2 1268/4885
US-11180493-B2 SGC stimulators GUCY1A2, GMPS, PDE2A ELANE 2411/4885CNR1 1432/4885CNR2 1255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.